
1. n engl j med. 2017 apr 27;376(17):1615-1626. doi: 10.1056/nejmoa1610528.

overexpression cytokine baff autoimmunity risk.

steri m(1), orrù v(1), idda ml(1), pitzalis m(1), pala m(1), zara i(1), sidore
c(1), faà v(1), floris m(1), deiana m(1), asunis i(1), porcu e(1), mulas a(1),
piras mg(1), lobina m(1), lai s(1), marongiu m(1), serra v(1), marongiu m(1),
sole g(1), busonero f(1), maschio a(1), cusano r(1), cuccuru g(1), deidda f(1),
poddie f(1), farina g(1), dei m(1), virdis f(1), olla s(1), satta ma(1), pani
m(1), delitala a(1), cocco e(1), frau j(1), coghe g(1), lorefice l(1), fenu g(1),
ferrigno p(1), ban m(1), barizzone n(1), leone m(1), guerini fr(1), piga m(1),
firinu d(1), kockum i(1), lima bomfim i(1), olsson t(1), alfredsson l(1), suarez 
a(1), carreira pe(1), castillo-palma mj(1), marcus jh(1), congia m(1), angius
a(1), melis m(1), gonzalez a(1), alarcón riquelme me(1), da silva bm(1), marchini
m(1), danieli mg(1), del giacco s(1), mathieu a(1), pani a(1), montgomery sb(1), 
rosati g(1), hillert j(1), sawcer s(1), d'alfonso s(1), todd ja(1), novembre
j(1), abecasis gr(1), whalen mb(1), marrosu mg(1), meloni a(1), sanna s(1),
gorospe m(1), schlessinger d(1), fiorillo e(1), zoledziewska m(1), cucca f(1).

author information: 
(1)from istituto di ricerca genetica e biomedica, consiglio nazionale delle
ricerche monserrato (m.s., v.o., m.l.i., m. pitzalis, m. pala, c.s., v.f., m.f., 
m. deiana, i.a., e.p., a. mulas, m.g.p., m. lobina, s.l., mara marongiu, v.s.,
michele marongiu, g.s., f.b., a. maschio, f.d., m. dei, f.v., s.o., a.a., m.b.w.,
a. meloni, s. sanna, e.f., m.z., f.c.), center advanced studies, research,
and development sardinia, parco scientifico e tecnologico della sardegna
(i.z., m.f., r.c., g. cuccuru), struttura complessa disciplina di ematologia e
centro trapianto cellule staminali emopoietiche wilma deplano, ospedale
oncologico di riferimento regionale armando businco (m. pani), dipartimento di
sanità pubblica, medicina clinica e molecolare, università di cagliari (e.c.,
j.f., g. coghe, l.l., g. fenu), azienda ospedaliera brotzu, s.c. neurologia
(p.f., m. melis), division rheumatology, university university hospital of
cagliari (m. piga, a. mathieu), department medical sciences m. aresu,
university cagliari (d.f., s.d.g., m.g.m.), azienda ospedaliera brotzu, u.s.
gastroenterologia pediatrica ospedale pediatrico microcitemico a. cao (m.c.), and
nephrology, dialysis, transplantation unit, giuseppe brotzu hospital (a.p.), 
cagliari, dipartimento di scienze biomediche, università degli studi di sassari
(m.f., f.p., f.c.), unit neurology, department clinical experimental
medicine, university sassari (g. farina, g.r.), servizio trasfusionale
(m.a.s.) clinica medica (a.d.), azienda ospedaliero universitaria di sassari,
sassari, neurology b, department neurological, biomedical, movement
sciences, university verona, verona (g. farina), department health
sciences, interdisciplinary research center autoimmune diseases, university of
eastern piedmont, novara (n.b., s.d.), sc neurologia, dipartimento di scienze
mediche, istituti di ricovero e cura carattere scientifico (irccs) casa
sollievo della sofferenza, san giovanni rotondo (m. leone), c. gnocchi
foundation irccs (f.r.g.), referral center systemic autoimmune diseases
fondazione irccs cá granda ospedale maggiore policlinico university milan 
(m. marchini), milan, dipartimento di scienze cliniche e molecolari,
università politecnica delle marche e ospedali riuniti, ancona (m.g.d.) - 
italy; laboratory genetics genomics, national institute aging, national
institutes health, baltimore (m.l.i., m.g., d.s.); department clinical 
neurosciences (m.b., s. sawcer) jdrf-wellcome trust diabetes inflammation
laboratory, national institute health research cambridge biomedical research 
centre, cambridge institute medical research (j.a.t.), university of
cambridge, cambridge, united kingdom; department clinical neuroscience,
karolinska institutet karolinska university hospital solna (i.k., i.l.b.,
t.o., j.h.), institute environmental medicine (l.a.) institute of
environmental medicine, unit immunology chronic disease (m.e.a.r.),
karolinska institute, center occupational environmental medicine,
stockholm county council (l.a.), stockholm; department functional biology,
university oviedo, oviedo (a.s.), rheumatology department, hospital
universitario 12 de octubre, madrid (p.e.c.), department internal medicine,
hospital universitario virgen del rocío, seville (m.j.c.-p.), laboratorio de
investigacion 10 rheumatology unit, instituto de investigacion
sanitaria-hospital clinico universitario de santiago, santiago de compostela
(a.g.), centro de genómica e investigación oncológica, pfizer-universidad de 
granada-junta de andalucía, granada (m.e.a.r.) - spain; department of
human genetics, university chicago, chicago (j.h.m., j.n.); centro hospitalar 
do porto-hospital santo antonio unit multidisciplinary research in
biomedicine-unidade multidisciplinar de investigação biomédica, porto, portugal
(b.m.s.); departments pathology genetics, stanford university, stanford,
ca (s.b.m.); center statistical genetics, university michigan, ann
arbor (g.r.a.).

comment in
    nat rev rheumatol. 2017 aug;13(8):456-457.

background: genomewide association studies autoimmune diseases mapped
hundreds susceptibility regions genome. however, few
association signals causal gene identified, even fewer 
the causal variant underlying mechanism defined. coincident associations
of dna variants affecting risk autoimmune disease quantitative
immune variables provide informative route explore disease mechanisms and
drug-targetable pathways.
methods: using case-control samples sardinia, italy, performed a
genomewide association study multiple sclerosis followed tnfsf13b
locus-specific association testing systemic lupus erythematosus (sle).
extensive phenotyping quantitative immune variables, sequence-based fine
mapping, cross-population cross-phenotype analyses, gene-expression
studies used identify causal variant elucidate mechanism of
action. signatures positive selection also investigated.
results: variant tnfsf13b, encoding cytokine drug target b-cell
activating factor (baff), associated multiple sclerosis well sle. 
the disease-risk allele also associated up-regulated humoral immunity
through increased levels soluble baff, b lymphocytes, immunoglobulins. the
causal variant identified: insertion-deletion variant, gctgt→a (in a
is risk allele), yielded shorter transcript escaped microrna
inhibition increased production soluble baff, turn up-regulated
humoral immunity. population genetic signatures indicated autoimmunity 
variant evolutionarily advantageous, likely augmenting
resistance malaria.
conclusions: tnfsf13b variant associated multiple sclerosis sle,
and effects clarified population, cellular, molecular levels.
(funded italian foundation multiple sclerosis others.).

doi: 10.1056/nejmoa1610528 
pmcid: pmc5605835
pmid: 28445677  [indexed medline]

